Advertisement American CryoStem, nanoRANCH to create new cancer treatment delivery methods - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

American CryoStem, nanoRANCH to create new cancer treatment delivery methods

US-based American CryoStem has entered into initial agreements with the nanoRANCH Division of UHV Technologies (nanoRANCH) to develop new methods for the delivery of therapeutics and drugs focused upon cancer treatments using adipose derived adult stem cells.

Under the deal, the company will be working with nanoRANCH’s Dan Dimitrijevich to create new treatment delivery methods using a combination of nanoRANCH technology and CRYO’s clinically processed ATCELLs.

The company’s research collaboration into cancer research and cancer related applications using CRYO’s clinically processed ATCELL products further expands relationships and potential applications to treat a wide range of diseases in the growing regenerative and therapeutic cellular therapy markets.

American CryoStem COO Anthony Dudzinski said the company is noticing a sharp increase in demand for its cutting edge clinically prepared cells and ancillary products for use in scientific development.

"Further we believe that the repeatable results that can be achieved with our ATCELL products are important to the development of the comparative data necessary to advance the use of adipose derived stem cells in regenerative medicine and cellular therapies," Dudzinski said.

Dimitrijevich said accurate targeting of pharmaceuticals is a continuing hurdle in drug delivery and particularly important are selectivity and specificity of anticancer agents.

"There is much to be learned from the trafficking and homing properties of immune system cells and stem cells as they navigate through the body.

"We are very fortunate to have available from American CryoStem, ATCELL, well defined and characterized stem cells that will serve as an excellent model system."